Based on the progress and results obtained in the first nine months of 2024, BioPorto maintains its financial guidance for 2024, as most recently described in its Interim Report for the Second Quarter ...

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?